

LIMAY BIOSCIENCES

Easy to use & affordable diagnostics
for underserved areas.

Lack of access to diagnostics hurt those who need it most



1.1 M

Avoidable deaths
per year



USD 750 B

Wasted yearly on
services from
inaccurate
diagnoses.



81 %

People in
low-income
countries lack
proper diagnosis.

FOUNDERS



CEO

MARCELO KAUFFMAN MD, PHD

Specialist in molecular and neurological genomics, co-founder and head of the Neurogenetics and Clinical Laboratory at the Ramos Mejia Hospital in Buenos Aires. Visiting researcher at the Gardner Center for Parkinson's Disease and Movement Disorders at the University of Cincinnati, USA. Researcher and passionate generator of knowledge in the field of neurogenetics.

CSO

DOLORES GONZÁLEZ MORÓN MD, PHD

Specialist in neurogenomics, former medical assistant at the University of Lausanne University Hospital in Switzerland. Co-founder of the Neurogenetics Clinic and Laboratory at the Ramos Mejía Hospital in Buenos Aires.

CBDO

FEDERICO SCAGLIOTTI

Entrepreneur. Graduate in Marketing. Founder of seven startups in various industries. Passionate about making things happen.

We are breaking barriers
to molecular diagnostic access

CENTRALIZED



PORTABLE

DELAYS



INSTANTANEOUS

COMPLEX



EASY TO USE

HIGH COSTS



LOW COSTS

We are solving this problem by facilitating access to affordable, simple and rapid molecular tests thanks to our state-of-the-art developments.

Our comprehensive solutions include: molecular biology, protein engineering and microengineering, all powered by artificial intelligence.

OUR ROADMAP

2025

🌿 Dengue virus test **market launch**
🦠 Respiratory infectious diseases test **market launch**

2026

🧬 **SAMR** test market launch
LATAM expansion and consolidation

2027

Southeast Asia expansion and consolidation
🧬 **CARB-R** test market launch

2028

🌿 🦠 🦠 **Global Market** reach



CONTACT

LIMAY BIO S.A.

942 Maipú street, 8th floor, CABA, Argentina
fs@limay.bio // +54 9 11 4056-5651

MARKET

Global molecular diagnostic market:
USD 49 billion

High-Burden LATAM Facilities Ready for POC
Molecular Testing:
USD 1.9 billion

Join the revolution & let's change the world!

